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Response of the intrarenal insulin-like growth factor-I axis to acute
ischemic injury and treatment with growth hormone and epidermal
growth factor. We previously reported that following bilateral acute
tubular necrosis (ATN) profound changes in the intrarenal insulin-like
growth factor-I axis occurs which are unrelated to altered nutritional
intake. In this current report we studied rats with unilateral ATN to assess
whether these changes reflect a response to acute injury or the accompa-
nying uremia. Compared to the contralateral kidney, the injured kidney
showed an increase in IGF-I receptor number without a change in IGF-I
receptor mRNA levels, a decrease in IGF-I mRNA and IGF-I protein
levels, a decrease in growth hormone (GH) receptor mRNA abundance
and receptor binding. There was also a decrease in IGF binding protein-2,
-3 and -5 mRNA levels together with a fall in protein products. Since this
unilateral ATN model excludes the influence of uremia and reduced
nutritional intake, we surmised that these changes reflect a direct response
to injury. Next, because of the reduced GH receptor binding noted above
and the reported decrease in epidermal growth factor (EGF) expression in
ATN, we tested the thesis that the low kidney IGF-I mRNA levels in ATN
are partly due to a relative or absolute deficiency of these hormones.
Administration of EGF or GH promptly increased ATN kidney IGF-I
mRNA levels to control kidney values, lending support to the thesis. The
response to EGF also suggests that the salutary effect of EGF treatment
in ATN may partly be mediated by stimulating IGF-I production.
Several studies have indicated that both circulating and locally
produced growth factors are important in modulating kidney
regeneration and repair following acute tubular necrosis (ATN)
[1]. While, their true role in the endogenous process has yet to be
established, systemic administration of transforming growth fac-
tor-a, epidermal growth factor (EGF), hepatocyte growth factor
or insulin-like growth factor-I (IGF-I) enhances renal recovery
after ATN [2—6]. To explore the role of IGF-I we recently
examined the response of the renal IGF-I axis to acute renal
failure following bilateral ischemic injury in rats [7]. This axis
includes IGF-I, and the receptors for IGF-I and growth hormone
(OH), and six insulin-like growth factor binding proteins (IGFBP)
[8, 9]. Binding proteins have a high affinity for IGF-I and serve as
a carrier or reservoir for the hormone and modulate its bioactivity
and are present in the circulation and in tissues throughout the
body [10, 11]. IGF-I release from IGFBP complexes is achieved
partly by circulating and tissue proteases which lower the IGFBP
affinity for IGF-I [11, 121. Protease activity may increase during
pregnancy and some pathologic conditions. Following acute isch-
emic renal injury, we noted that the expression of several of the
gene encoding components of the local IGF-I system was de-
pressed [71. The mRNA levels of IGF-I, the GH receptor and
IGFBP-2 through 5 were reduced significantly, while IGFBP-1
levels were not significantly affected. Kidney IGF-I content also
fell. Interestingly, while IGF-I receptor mRNA levels were un-
changed, the number of IGF-I receptors increased markedly.
Since the IGF-I axis is sensitive to nutritional changes [13], we
controlled for the reduced food intake that accompanies acute
renal failure and showed that the changes noted above were not
nutritionally induced. However, it is conceivable that the changes
in gene expression were a consequence of the accompanying
uremia and do not reflect a direct response to injury. It is also
conceivable that the reduced IGF-I mRNA levels may reflect a
relative or absolute deficiency of two key inducers of kidney IGF-I
gene expression, namely GH and EGF, rather than an inability of
the cells to express the IGF-I mRNA. We propose that there may
be a relative deficiency of GH since GH receptor gene expression
is reduced in ATN [71. If this results in less GH hormone receptor
binding, then this would diminish GH induced stimulation of
IGF-I production. In respect to EGF it is well established that
EGF promotes IGF-I gene expression [141, and that in ATN
preproEGF gene expression and kidney total EGF content is
depressed [15—16].
In this study we first tested whether the alterations of the renal
IGF-I axis following bilateral ATN reflects a direct response to
injury or a manifestation of uremia. To this end we studied
unilateral ATN so as to control for the effects of uremia and also
nutrient intake. Next we tested whether reduced kidney IGF-I
gene expression might reflect a relative or absolute deficiency of
OH or EGF. To this end we examined the response of the injured
kidney to OH or EGF treatment.
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Male Sprague Dawley rats (— 200 g) were anaesthetized with
ketamine (60 mg/kg) and xylazine (12 mg/kg) and the body
temperature was maintained at 37°C. The left kidney was exposed
via a flank incision. In half the rats the renal pedicle was clamped
for 30 minutes (experimental group) while the other rats served as
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sham operated controls. After closure of the wounds the rats were
allowed to recover from anesthesia and placed in individual cages.
The two groups of rats were pair-fed to control for any influence
of dietary uptake on the intrarenal IGF-I axis. Two and seven days
later the rats were anaesthetized, blood was collected and their
kidneys excised. Kidneys were rapidly decapsulated, weighed,
frozen in liquid nitrogen and stored at 80°C until processing.
Sections of the kidney were also fixed in 10% formalin for
histological analysis. To measure kidney IGF-I content and recep-
tor binding, a second batch of rats were prepared as before. At
sacrifice the kidneys were flushed in situ with phosphate buffered
saline (37°C) until free of blood, and the kidneys were collected
and stored as above. To test the effect of GH and EGF adminis-
tration on IGF-I gene expression a third batch of rats was
prepared as above. Two days later the rats were treated with I mg
bovine OH (bGH), or 20 jsg EGF or vehicle alone which was
given s.c. The animals were sacrificed six hours later and the
kidneys were collected and stored at —80°C. Bovine GH was a gift
from the USDA animal Hormone Program (Beltsville, MD, USA)
and EGF was purchased from R&D Systems (Minneapolis, MN,
USA).
Preparation of crude kidney membranes
Crude plasma membrane were isolated from half of each
kidney as we previously described in detail [7]. This involved
disruption of the kidney by homogenization followed by differen-
tial centrifugation in 8% buffered sucrose and collection of a
47,000 g pellet. The pellet was resuspended in calcium-free
Krebs-Ringer Hepes buffer (KRH, pH 7.4) and stored at —80°C.
Membrane protein content was measured using the Bio-Rad
method (Bio-Rad Laboratories, Richmond, CA, USA).
Membrane receptor binding assay
For measuring 1251-IGF-I and 1251-GH binding, recombinant
human IGF-I and recombinant human GH (hGH), gifts from
Genentech Inc. (South San Francisco, CA, USA), were radiola-
beled with 1251-Na (< I iodine atom/molecule) by a chloramine T
[17] or iodogen method, respectively [18].
IGF-J receptor binding. Binding of '251-IGF-1, 10 M, to crude
plasma membranes (60 tg protein) was measured in calcium-free
KRH containing 0.1% BSA, 2 mM bacitracin and 5 mivi N-
ethylmaleimide. The membrane suspension was incubated at 4°C
overnight. Membrane-bound and free 1251-IGF-I were separated
by centrifugation at 12,000 g for 15 minutes. The supernatant was
aspirated and the membrane pellets were washed with 0.5 ml of
KRH, the tips of the centrifuge tubes excised and radioactivity
determined in a gamma counter. Nonspecific binding of 125J
IGF-l was determined from the radioactivity that associated with
membranes in the presence of 106 M of unlabeled IGF-I. This
value was subtracted from total binding to yield specific binding.
The data from competition curves were subjected to Scatchard
analysis to determine binding affinity and receptor number [19].
Degradation of '251-IGF-1 in the binding assay was assessed as the
appearance of radioactivity soluble in 10% trichloroacetic acid
(TCA) and averaged < 5% of total counts.
GH receptor binding. Total specific binding and somatogenic
specific binding of 1251-hGH was determined in the absence or
presence of cold hGH or bovine GH, respectively. Human GH
binds to both the lactogenic and somatogenic receptors in the rat
while bGH binds to the OH receptor only [20, 21]. Binding of
1251-hGH, 5 X 10' M, to crude membranes (200 tg protein) was
measured in calcium-free KRH containing 0.5% BSA, 2 mM
bacitracin and 5 mrvi N-ethylmaleimide in the absence or presence
of cold hGH or bGH. The membrane suspension was incubated at
4°C overnight. Degradation of 1251-hGH in the binding assay was
negligible.
Cross linking of '251-IGF-I receptor
12514GF4 was cross linked to kidney membranes according to
methodology described by Pillion, Haskell and Meezan [22].
Aliquots of crude membrane preparations, (200 tg of protein)
were incubated at 4°C overnight with 10'° M 1251-IGF-I in the
presence or absence of i0— M cold IGF-I or insulin. Membranes
were washed twice and resuspended in Krebs Ringers Hepes
buffer (KRH), pH 7.5. Cross linking of the alpha1 subunit of IGF-I
receptor was carried out in the presence of 0.25 mivi disuccinimidyl
suberate at 4°C for 15 minutes. Cross linking was stopped by the
addition of 10 m'vi Tris-HC1 with 1 mM EDTA, pH 7.5. Samples
were washed twice. The pellets were resuspended in 20 jil of SDS
sample buffer with 1% 2-mercaptoethanol as a reducing agent,
heated at 95°C for 90 seconds, and subjected to 5 to 15% gradient
SDS-polyacrylamide (PAGE) gel electrophoresis. The radioactiv-
ity in the gel was visualized by autoradiography. Molecular
weights were determined by comparison with prestained markers
from BioRad (Richmond, CA, USA).
Western ligand blot
Plasma membranes were prepared from saline perfused whole
kidneys as described above. Membrane protein, 100 jig, was
electrophoresed in 12% SDS-polyacrylamide gel. Separated pro-
teins were electroblotted onto nitrocellulose filters (Biorad Semi-
Dry Transfer Cell) and then incubated with 1,000,000 cpm of
1251-IGFJ and 1251-IGF-II overnight at 4°C and visualized by
autoradiography [231. Cytosolic protein (100,000 g supernatant)
was also analyzed, but no signal was detected with 100 jig cytosolic
protein.
Kidney binding protein protease activity
Protease activity in the kidney was measured according to
methodology described by Davenport et al [24]. Briefly, 50 jig of
kidney homogenate were incubated with 2 d of normal rat serum
at 37°C for 10 minutes to two hours. Shorter incubation time was
required when measuring proteolysis of the 24 and 30 kD serum
IGFBPs than when measuring activity against the 40 to 42 kD
IGFBP which corresponds to the size of IGFBP-3. The optimal
incubation time was based on preliminary experiments. The
reaction was stopped by adding SDS sample buffer and heated at
100°C for five minutes. The IGFBP levels in samples before and
after incubation were then assayed by Western ligand blot analysis
as described above. Protease activity was estimated from the
densitometric analysis of the autoradiographic signals.
Estimation of serum and kidney concentration of IGF-I by
radioimmunoassay
IGF-I was measured by radioimmunoassay (RIA) in acid-
ethanol extracts prepared from serum and saline perfused kidneys
as previously described from this laboratory [71. The extraction,
which separates IGF-I from its binding proteins, was based on that
described by D'Ercole et al [25, 26]. A commercial RIA kit was
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used (Nichols Institute, San Juan Capistrano, CA, USA). Recov-
ery of IGF-I added to homogenate of right control kidneys and
left ischemic kidneys averaged 78 4.1 and 81.5 3.8%,
respectively, and to serum 88 3.2 and 94 3.4%, respectively.
Results are corrected for recoveries.
RNA extraction
Total RNA was isolated separately from the left (injured) and
right (uninjured) kidney of experimental rats and from the left
kidney of sham operated rats. The acid guanidinium thiocyanate-
phenol chloroform single step method of Chomczynski and Sacchi
[27] was used to extract RNA which was quantified spectropho-
tometrically by absorbance at 260 nm. Integrity was confirmed by
analysis of the ethidium bromide-stained 18S and 28S ribosomal
RNA bands separated by agarose gel electrophoresis.
Northern blot analysis
Total RNA was size-separated by agarose gel electrophoresis.
In brief, RNA was denatured with 0.55 M formaldehyde. RNA, 20
jtg, was added into each lane and electrophoresed on a denaturing
agarose gel containing 0.55 M formaldehyde. RNA was transferred
by capillary action onto nitrocellulose filters which were then UV
cross linked on both sides (UV 1800 Stratalinker, Stratgene, La
Jolla, CA, USA) and stored for hybridization. The filters were
then prehybridized at 42°C for four hours in a hybridization
solution consisting of 50% formamide, 1.5 X SSPE, 2.5 X
Denharts solution, 50 tg salmon sperm DNA, 0.2% SDS. The size
and amount of IGF binding protein mRNA was determined by
hybridizing the mRNA on the filter to 32P-labeled cDNA probes
of rat IGFBP-1, -2, -3, -4, -5 (gifts from Dr. Shimisaki, Whittier
Institute, La Jolla, CA, USA). Probes, - 2.5 million cpm/ml, were
hybridized to the respective mRNAs on Northern blots in fresh
hybridization solution at 42°C overnight. Filters were then washed
and exposed to Kodak XAR films (Kodak, Rochester, NY, USA)
at —70°C for one to seven days. The abundance of each IGFBP
mRNA was measured by scanning densitometry (Ultrascan XL;
Pharmacia LKB Biotechnology, Inc., Alameda, CA, USA) and
adjusted for the levels of the 18S rRNA readings. These were
obtained from photographic negatives of the nitrocellulose filters
[7]. The 18S rRNA levels in kidneys two and seven days post-
ischemia did not differ from that measured in sham-operated
control kidneys.
Solution hybridizationiRNAse protection assay
Nuclease protection assays were performed as previously de-
scribed [71. In brief, labeled antisense IGF-I and IGF-I receptor
RNAs were synthesized using 32P-labeled CTP. Total RNA, 20
was hybridized with - 200,000 cpm of alpha-32P-CTP labeled
antisense IGF-I or IGF-I receptor RNA probes overnight at 42°C
in 75% formamide/400 mM NaC1. After hybridization, the mixture
was added to RNAse digestion buffer containing RNAse A (25
tg/ml) and RNAse T1 (50 U/mI) and incubated at 30°C for one
hour. After that, proteinase K (200 jg/ml) was added and
incubation continued at 37°C for 30 minutes. Protected hybrids
were then separated by ethanol precipitation and size-separated
on a 5% polyacrylamide/8 M urea denaturing gel. Protected bands
were measured by densitometry of the autoradiograph.
Polymerase chain reaction (PCR) assay
GH receptor mRNA and 18S rRNA levels were measured
simultaneously with a gene Amp RNA-PCR kit (Perkin Elmer
Cetus, Norwalk, CT, USA) [28]. Total RNA was reverse tran-
scribed by using random hexamers. Oligonucleotide primers for
the GH receptor were designed to amplii' a 185 base pair DNA
fragment. The fragment included 26 bases in exon 9 and 159 bases
in exon 10. Both exons are in the intracellular domain of the rat
GH cDNA sequence [29]. GH receptor mRNA was amplified by
28 PCR cycles and 18S rRNA, used as an internal control, was
amplified in the same assay tube for the last 10 cycles by adding
specific 18S rRNA primers. The 18S rRNA primers amplified 140
bases spanning nucleotide positions 107 to 246 in the human
cDNA sequence [30]. PCR products were separated on a 5%
polyacrylamide/8 M urea gel and analyzed by quantitative autora-
diography.
Preparation of radiolabeled probes
For the solution hybridization/RNase protection assay, radiola-
beled antisense IGF-I, IGF-I receptor and 18S riboprobes were
prepared with [32P]-CTP as we previously described [7]. The
IGF-I riboprobe, a 376 bp Sau3A-EcoRI fragment, was designed
to detect both the Ea and Eb IGF-I mRNAs [31]. The IGF-I
receptor riboprobe contained 280 bases complementary to the
IGF-I receptor mRNA. For Northern blot analysis the eDNA
probes were labeled with 50 tCi [32P]-dCTP (3000 Ci/mmol,
Amersham, Arlington Heights, IL, USA) by a random primer
method (DNA labeling kit 70200, United States Biochemical
Corporation, Cleveland, OH, USA). Purification of radiolabeled
cDNA probes were achieved through a G-50 Sephadex column.
The eDNA probes for the five IGFBPs studied were prepared
from rat cDNAs cloned into recombinant plasmid vectors (pBlue-
scriptSK) which were gifts of Dr. S. Shimasaki (Whittier Insti-
tute, La Jolla, CA, USA). Probes were prepared by synthesizing
the corresponding cDNA by PCR using the cloned eDNA as a
template [32]. The IGFBP-1 probe consisted of 407 bp corre-
sponding to the coding region spanning nucleotide position 486 to
892 in the rat IGFBP-1 cDNA sequence. The IGFBP-2 probe was
comprised of 342 bp spanning the nucleotide position 670 to 1011.
The IGFBP-3 probe comprised 636 bp spanning nucleotide
positions 196 to 831. The IGFBP-4 probe consisted of 354 bp
spanning the nucleotide position 487 to 840. The IGFBP-5 probe
comprised 259 bp spanning nucleotide positions 856 to 1114.
Data analysis
Autoradiographic densitometry readings of the mRNAs of
interest were adjusted for the corresponding 18S rRNA reading.
For IGF-I we measured the Ea IGF-I mRNA transcripts only, and
it accounted for > 95% of the IGF-I mRNA signal. Results are
expressed as the mean SCM. The average of the controls was
assigned a value of unity and all results were expressed in relation
to this value. Differences between the injured and contralateral
control kidneys were evaluated using Student's two-tailed paired
I-test. P values of < 0.05 were taken as significant. Differences
between groups were analyzed by Student's unpaired I-test when
appropriate.
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Results
On entry into the study the body wt of sham operated control
and unilateral ATN rats were similar (206 2 vs. 208 2 g) and
did not differ two and seven days after surgery (200 2 vs. 202
2 g and 228 4 vs. 226 2 g, respectively). Unlike the situation
after bilateral ATN [71, weight loss did not occur and by the
seventh day both groups had gained - 20 g in weight. The serum
creatinine levels two days after unilateral ATN (0.42 0.02
mg/dl) did not differ significantly from control values. Light
microscope examination of periodic acid-Schiff stained kidney
sections obtained two days after the ischemic episode revealed
widespread necrosis of proximal tubules, most marked in the S3
segments, tubular dilatation and vascular congestion in the outer
medulla.
Kidney mRNA levels
The relative IGF-I mRNA levels were significantly reduced two
and seven days after ischemic injury (Figs. 1A and 2). On day 2 it
averaged 47% and on day 7, 38% of the contralateral control
value (P < 0.01). The relative IGF-I receptor mRNA levels in the
ATN kidneys, measured two and seven days after surgery, were
similar to the levels seen in the contralateral kidney (Figs. lB and
2).
The relative mRNA levels of IGFBP-1, -2, -3, -4 and -5 were
also altered after injury and are shown in Figures 3 and 4. On day
2 after injury, the abundance of the IGFBP-2, -3, and -5 mRNAs
decreased by 34, 70 and 76%, respectively, in the ATN kidneys
when compared to the contralateral uninjured kidney (P < 0.05);
IGFBP-4 mRNA levels were unchanged. At this time IGFBP-1
mRNA levels were increased by 56% (P < 0.05). On day 7 after
injury, the mRNA levels for IGFBP-2, -3 and -5 returned to
baseline, but IGFBP-1 mRNA levels were still elevated. Interest-
ingly, IGFBP-4 mRNA levels were increased threefold at this
time. In contrast the relative GH receptor mRNA levels were
reduced significantly in the injured kidneys (Fig. 5), and were on
average half of their respective contralateral control values on the
two study days (44 4.1% and 58 6.6%, respectively; P < 0.01).
Note the mRNA levels of all the genes measured in the
contralateral uninjured control kidneys did not differ significantly
from the levels in the kidneys from sham operated rats. Thus the
presentation of data are confined to comparisons between the
injured and uninjured kidneys.
Plasma membrane IGF-I receptor binding
In contrast to the IGF-I receptor mRNA data noted above, two
days after surgery, IGF-I binding to plasma membranes from
ATN kidneys exceeded the values in the contralateral controls by
37% (14.5 0.4 vs. 10.6 0.3%160 g protein, P < 0.01). On day
7 binding to the membranes from ATN kidneys exceeded the
control values by 91% (14.7 1.1 vs. 7.7 0.5%, P < 0.01). The
differences between the contralateral and ATN kidneys is readily
apparent from the competitive displacement curves shown in
Figure 6. When the data were expressed as a percent of maximum
'251-IGFI bound, the curves were superimposable. This indicates
that receptor affinity was similar in the two groups (Fig. 6 insert).
These same curves were used to determine the concentration of
IGF-I at which '251-IGF-I binding was 50% of maximum, a
measure of relative receptor affinity. For control and experimental
membranes from day 7 experiments, this averaged 0.65 and 0.79
Fig. 1. Relative IGF-I (A) and IGF-I receptor (B) mRNA levels in kidneys
from contralateral control and ATN kidneys two and seven days after 30
minutes of ischemic injury. IGF-I and IGF-I receptor mRNA and 18S
rRNA levels were measured simultaneously in solution hybridization
RNase protection assays and autoradiograms quantified by densitometry.
The IGF-I and IGF-I receptor signals were corrected from the 18S rRNA
signal. The average of the control values were then assigned an arbitrary
unit of one and all readings were expressed relative to this unit. Results
are the mean SEM of 5 rats per time point, *P < 0.01.
nM, respectively. This also shows that receptor affinity was similar
in the two groups. Scatchard analysis of the high affinity binding
components also confirmed that receptor affinity (0.5 vs. 0.5 nrvi,
ATN vs. controls) was identical between the groups. The number
of IGF-I receptors in the ATN kidney membranes was twice the
number measured in the controls (79 vs. 41 pM/60 .rg membrane
protein, P < 0.001). These results are consistent with our findings
in acute renal failure following bilateral ATN. It is likely that the
increase in IGF-I receptor number in the injured kidneys reflects
post-translational up-regulation, since IGF-I receptor mRNA
levels were unchanged.
The covalent cross linking experiments (Fig. 7) demonstrate
that IGF-I binds specifically to the IGF-I receptor. In the auto-
radiogram, the 1251-IGF-I signal appears in the position of a
protein of Mr 130 kD which is consistent with the alpha1
subunit of the IGF-l receptor. Binding was blocked by i0 M
IGF-I but not by insulin. The intensity of the signal was greater in
Fervenza et al: Insulin-like growth factor I 347
IGE-Ir
IGF-1
Control ATN
*
IGFBP-2 IGFBP-3
Day 2
H — H -t Ia1 o at jel
( I
0--
IGFBP-1 IGFBP-4 IGFBP-5
the ATN membranes and is consistent with the greater abundance
of IGF-I receptors in this group. In an earlier study we verified
that membrane binding of 1251-IGF-I was IGF-I receptor specific
[7]. This included the demonstration that membrane '251-IGF-I
binding was inhibited to a similar extent by IGF-I and des [1—31
IGF-I, an analogue with low affinity for the IGFBPs.
Fig. 2. A representative autoradiogram of a
solution hybridization RNase protection assay for
IGF-I and the IGF-I receptor mRNA, and the
18S rRNA levels in kidneys from contralateral
control and ATN kidneys two days after surgely.
Fig. 3. Relative mRNA levels of IGFBP-1, -2, -3,
-4, and -5 from contralateral control or A TN
kidneys on day 2 after injuly. mRNA levels were
detected by Northern blot analysis and
corrected for the 18S rRNA signal. Results
were analyzed and expressed as described in
Figure 1 and are from 5 rats per time point.
Representative Northern blots are shown.
*p < 0.05.
As shown in Figure 8, Western ligand blot analysis demon-
strated two IGFBPs of molecular weight approximately 24 and 30
Plasma membrane GH receptor binding kD each. At day 2, the signals for both proteins were significantly
Total hGH binding to plasma membranes from ATN kidneys lower with the ATN membranes. Densitometry showed a 24%
was significantly reduced compared to the contralateral control reduction in the 24 kD protein signal from the ATN membranes
membranes (3.6 0.2% vs. 5.94 0.52%, respectively; P < 0.05). compared to the contralateral control (0.22 0.01 vs. 0.29 0.02
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Also, in ATN, the somatogenic component showed reduced
binding compared to control kidney membranes (0.52 0.06% vs.
1.36 0.09%, respectively; P < 0.001).
Western ligand blot for membrane associated IGFBPs
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Fig. 4. Relative mRNA levels of IGFBP-J, -2, -3,
-4, and -5 from contralateral control or A TN
kidneys on day 7 after injuly. Results were
analyzed and expressed as described in Figure 1
and are from 5 rats per time point.
Representative Northern blots are shown.
*p < 0.05.
Fig. 5. Relative GH receptor mRNA levels. GH
receptor mRNA and 18S RNA levels were
determined simultaneously by quantitative
PCR. The relative GH receptor mRNA levels
were calculated as described in Figure 1. N = 5
rats per time point. Representative
autoradiographs from day 2 and 7 are shown.
P < 0.01.
arbitrary densitometry units, respectively; P < 0.05). The corre-
sponding values for the 30 kD protein averaged 0.21 0.01 and
0.354 0.01 arbitrary units, respectively; this represents a 41%
reduction in this signal (P < 0.05). At day 7, the values for the 24
and 30 kD protein signal were on average lower in ATN mem-
branes but did not reach statistical significance (data not shown).
Protease activity
To determine whether the lower ATN plasma membrane
associated IGFBPs might be due to increased degradation we
measured IGFBP protease activity. As depicted in Figure 9,
IGFBP proteases activity was readily detected in homogenates of
the injured and the contralateral control kidneys. To measure
proteolytic activity against the 40 to 42 kD serum IGFBP protein
(IGFBP-3), homogenate was incubated at 37CC with normal test
serum for 120 minutes. At the end of this period the 40 to 42 kD
serum IGFBP signal was reduced significantly (P < 0.01) and
averaged 41 6% and 31 4% of the preincubation value in the
ATN and contralateral kidney homogenates, respectively. To
measure proteolytic activity against the 30 kD serum IGFBP
a
. E
•o ><a ac2.
5- 0
.0
I II II II II II
Buffer IGF-I Insulin Buffer IGF-l Insulin
protein, homogenate was incubated with test serum for 10 min-
utes. The 30 kD signal fell significantly to 41 8% of its
preincubation value in contralateral kidney homogenate and to 60
13% in the ATN kidney homogenate (P < 0.01). Proteolytic
activity against the 24 kD serum IGFBPs was also present and
over a 60-minute incubation period the 24 kD signal fell to less
then 10% of the preincubation value in both kidney groups. In all
instances there was no significant difference in the proteolytic
activity of ATN compared to control kidneys. Endogenous pro-
teolytic activity was not detected in normal plasma. These findings
demonstrate that kidney tissue contains proteases that are active
against IGFBPs and that this activity is not increased in ATN
—
Fig. 7. Autoradiograph of 25I-IGF-I (10'° M)
cross linked to the a1-subunit of the IGF-I
32 5 receptors on kidney membranes from contralateral— control and A TN kidneys on day 2 after injuly.
Membranes were incubated with '251-IGF-I in
the presence of buffer alone, iO M unlabeled
IGF-I or iO M insulin. Binding was blocked
by IGF-I but not by insulin.
kidneys. Thus the lower levels of plasma membrane associated
IGFBPs are not due to altered kidney protease activity.
Serum and kidney immunoreactive IGF—I levels
Serum IGF-I concentrations in the rats with unilateral ATN
were similar to levels obtained in sham operated rats. On day two,
the values in ATN and sham operated rats were 1033 39 and
1044 49 ng/ml, respectively. On day seven the values were 945
48 versus 1053 22 nglml, respectively. Kidney IGF-I levels
were determined two days after injury and were reduced by half in
the ATN kidneys compared to the contralateral control kidneys
(2.25 0.2 vs. 4.52 0.52 nglmg protein, respectively; P < 0.01).
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Fig. 6. Competitive inhibition of '251-IGF-I
binding to plasma membranes from contralateral
control () and A TN (•) kidneys. Results are
7 the mean of three separate experiments seven
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expressed as a percent of maximal binding.
II
M, (kD)
— 205
—116.5
—80
30 kD
24 kD
Fervenza et al: Insulin-like growth factor I 351
Control ATN
Fig. 8. Representative Western ligand blot of plasma membrane-associated IGF binding proteins. Membranes were prepared from saline perfused
contralateral control and ATN kidneys two days after the ischemic insult. Membranes were pooled from 5 rats from each group and assayed in triplicate.
Since both kidneys are exposed to the same circulating serum
IGF-I levels this finding together with the reduced kidney IGF-I
mRNA levels suggests attenuated kidney IGF-I production.
Effect of GH and EGF on IGF-I gene expression
The effect of GH treatment on the IGF-I niRNA levels is
depicted in Figure 10. In vehicle treated rats, as described earlier,
the relative IGF-I mRNA levels in injured kidneys were reduced
significantly when compared to the contralateral control kidneys.
In contrast, in the GH treated rats, kidney IGF-I mRNA levels in
the injured kidney were restored to values that did not differ from
the contralateral uninjured control kidney. Treatment with EGF
also restored IGF-I mRNA levels to values that did not differ
significantly from the contralateral uninjured control kidneys.
This is depicted in Figure 11.
Discussion
Previously we reported that bilateral acute ischemic kidney
injury, sufficient to produce severe acute renal failure, is followed
by changes in the renal GH—IGF-I axis that could not be
attributed to reduced food intake [7]. While this likely reflects a
response to injury, it is conceivable that the changes observed are
related to the accompanying renal failure since uremia may affect
gene expression. For example, in chronic uremia the mRNA levels
for the hepatic GH receptor [33] and the cardiac Na,K-ATPase
cs-2 and f3-2 subunits decrease [34, 35], while PTH mRNA levels
increase [361. Also, in chronic renal failure, skeletal muscle IGF-I
mRNA levels fall while IGF-I receptor mRNA levels rise [37].
In the present study we used a model of unilateral ischemic
ATN to tease out the renal response to acute injury without the
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NS
Fig. 10. Relative JGF-I mRNA levels in kidneys
from rats receiving I mg bGH (treated) or vehicle
(untreated) two days after unilateral ischemic
injwy. GH or vehicle was given sc six hours
prior to sacrifice. IGF-I mRNA and 18S rRNA
levels were measured simultaneously in solution
hybridization RNAase protection assays and
autoradiograms quantified by densitometry. The
IGF-I signal was corrected for the 18S rRNA
signal. The average of the initial control values
were then assigned an arbitrary unit of one and
all readings were expressed relative to this unit.
Representative autoradiograms from the same
gels are shown.
Fig. 11. Relative IGF-I mRNA levels in kidneys
from rats receiving 20 jig EGF (treated) or
vehicle (untreated) two days after unilateral
ischemic injury. EGF or vehicle was given s.c.
six hours prior to sacrifice. Results were
analyzed as described in Figure 10.
Representative autoradiograms from the same
gels are shown.
confounding effects of uremia or dietary changes. Compared to IGF-I gene expression has also been reported following acute
the opposite uninjured kidney, IGF-I mRNA levels were reduced renal injury due to gentamycin and mercuric chloride nephrotox-
by approximately 50% two days after injury and remained low icity [6, 38, 391. The observed fall in IGF-1 mRNA levels following
after seven days. Kidney immunoreactive IGF-I levels were also ischemic injury together with the reduced IGF-I protein levels
reduced at this time. These findings are consistent with our implies that total kidney IGF-I production is reduced at a time
observations in rats with bilateral ATN and indicate that these when IGF-I would be of particular value in the healing process.
changes are a direct response to injury [7]. Decreased kidney On the other hand, Matejka and co-workers [40, 41] reported that
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after acute renal injury IGF-I mRNA and protein levels are
transiently expressed in regenerating nephron segments that do
not normally express IGF-I. In addition, non-tubular cells, pre-
dominantly macrophages, are IGF-I positive. This more wide-
spread expression of IGF-I abated one week after injury. These
findings suggest that local IGF-I may play a role in early renal
regeneration. However, since administration of recombinant
IGF-I accelerates recovery [3—51, it appears that the spontaneous
local response is not optimal.
We also observed that kidney IGF-I receptor number increased
after unilateral ATN as reported following bilateral ATN [7, 40].
Thus, this kidney response appears to be induced by injury and
not dietary deficiencies or uremia. Since kidney IGF-I receptor
mRNA levels were unchanged, the increase in receptor number is
likely a post-transcriptional event, perhaps a response to low
tissue IGF-I levels. In our earlier study of bilateral ATN we noted
a strong correlation between the severity of renal failure and
receptor number, and postulated that the increase in receptor
number will likely favor the renal action of circulating and local
IGF-I [7].
Some similarities and some differences were noted in expres-
sion of the IGFBP genes in response to unilateral ATN when
compared to our previous findings following bilateral ATN [7].
First, the decrease in the IGFBP-2, -3, and -5 mRNA levels after
unilateral ATN were similar to the pattern seen in bilateral ATN.
Two days after injury, mRNA levels of these binding proteins
decreased significantly to between 34 and 76% of the control
values, and by seven days had returned to baseline. On the other
hand, the change in IGFBP-4 mRNA levels differed from that
observed with bilateral ATN that was followed by a fall in
IGFBP-4 mRNA levels. After unilateral injury, IGFBP-4 mRNA
levels were unchanged two days later, but by day seven the levels
had increased twofold. There were also differences in the IGFBP-
1 response. The IGFBP-1 mRNA level increased by near half on
the second day after unilateral injury and was still elevated on the
seventh day. Following bilateral ATN there were no significant
changes in the IGFBP-1 mRNA level. We also measured the
plasma membrane associated IGFBPs by Western blot analysis
and found that the proteins identified (molecular wt '— 24 and 30
kD) were reduced by 24% and 41%, respectively, two days
following ATN. This presumably reflects reduced IGFBP produc-
tion since IGFBP protease activity was not increased in the ATN
kidney. While the exact role of each kidney IGFBP is not known,
they do bind IGF-I with high affinity, serve as a reservoir of IGF-I
and deliver it to target cells [10]. We suggest that with reduced
IGFBP levels, a larger proportion of the kidney IGF-I will be in
the free form. This together with the increase in receptor number
will likely augment the bioavailability of IGF-I.
Growth hormone is a potent regulator of kidney IGF-I produc-
tion [42]. In experimental uremia, GH receptor gene expression is
reduced in part because of reduced nutritional intake, but largely
because of the uremic state per se [33]. In this study of unilateral
ATN we noted that, as occurs after bilateral ATN [7], kidney GH
receptor mRNA levels are reduced; furthermore, we showed for
the first time that GH receptor binding is reduced. Thus these
changes appear to occur in response to acute renal injury and are
not a consequence of uremia. Because of this reduction in GH
receptor gene expression and receptor binding we postulated that
a state of GH resistance might ensue and this could contribute to
the low IGF-I mRNA and protein levels seen after ATN. Treat-
ment with a single dose of bovine GH two days after injury rapidly
stimulated IGF-I mRNA levels to values that did not differ
significantly from the opposite uninjured kidneys.
Epidermal growth factor is another potent regulator of IGF-I
production in the kidney and is coexpressed with IGF-I in the
same nephron segment, namely in the thick ascending loop of
Henle. The EGF protein is normally localized to the apical cell
membrane. Following ischemic ATN preproEGF mRNA levels,
total kidney and membrane bound EGF protein concentrations
and total urinary EGF excretion fall; soluble EGF levels increase
[15, 16, 43]. Since EGF stimulates kidney IGF-I gene expression
[14], we postulated that reduced total kidney EGF production
may partly account for the reduced IGF-I mRNA level. As with
the GH experiments, rats were given a single dose of EGF two
days after ischemic injury and IGF-I mRNA levels were measured
six hours later. EGF treatment restored IGF-I mRNA levels to
values that did not differ significantly from the contralateral
uninjured kidneys. This early response after EGF administration
argues against increased IGF-I gene expression due to accelerated
regeneration, and provides support for our thesis. It also suggests
that enhanced recovery from ATN after EGF administration may
in part be mediated by EGF stimulated IGF-I production [2, 44].
In summary, we have shown that ischemic ATN produces
profound changes in the intrarenal IGF-I axis that are indepen-
dent of uremia or nutrient intake and thus represent a tissue
response to injury. Furthermore, we demonstrated that GH or
EGF treatment corrects the attenuated IGF-I gene expression in
injured kidneys, and this lends support to the thesis that the low
IGF-I mRNA levels reflect an absolute or relative deficiency of
these factors. This response to EGF also raises the possibility that
the reported accelerated recovery after EGF treatment of ATN
may, in part, be mediated through augmented kidney IGF-I
production. Finally, the finding that IGF-I receptor number is
increased while plasma membrane associated IGFBPs are re-
duced in ATN kidneys leads us to surmise that this is an
advantageous response that likely renders the damaged kidney
more responsive to the salutary effects of endogenous and admin-
istered IGF-I.
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